Fulcrum Capital LLC Increases Holdings in Edwards Lifesciences Co. (NYSE:EW)

Fulcrum Capital LLC lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 3.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 122,012 shares of the medical research company’s stock after buying an additional 4,107 shares during the period. Edwards Lifesciences comprises 1.9% of Fulcrum Capital LLC’s investment portfolio, making the stock its 17th largest position. Fulcrum Capital LLC’s holdings in Edwards Lifesciences were worth $9,033,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of EW. Williams Financial LLC purchased a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $201,000. Oppenheimer & Co. Inc. boosted its position in shares of Edwards Lifesciences by 40.0% during the second quarter. Oppenheimer & Co. Inc. now owns 36,745 shares of the medical research company’s stock valued at $3,394,000 after purchasing an additional 10,492 shares in the last quarter. Meeder Advisory Services Inc. boosted its position in shares of Edwards Lifesciences by 39.5% during the second quarter. Meeder Advisory Services Inc. now owns 9,933 shares of the medical research company’s stock valued at $918,000 after purchasing an additional 2,813 shares in the last quarter. Thoroughbred Financial Services LLC boosted its position in shares of Edwards Lifesciences by 165.4% during the second quarter. Thoroughbred Financial Services LLC now owns 15,334 shares of the medical research company’s stock valued at $1,416,000 after purchasing an additional 9,556 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its position in shares of Edwards Lifesciences by 2.9% during the second quarter. Oppenheimer Asset Management Inc. now owns 21,983 shares of the medical research company’s stock valued at $2,031,000 after purchasing an additional 615 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

Shares of NYSE EW traded down $1.64 during mid-day trading on Monday, reaching $71.78. The company’s stock had a trading volume of 3,397,817 shares, compared to its average volume of 3,838,476. The firm has a market capitalization of $42.34 billion, a PE ratio of 10.36, a P/E/G ratio of 3.61 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock has a fifty day moving average of $71.64 and a two-hundred day moving average of $71.92. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period in the prior year, the company earned $0.59 earnings per share. The firm’s revenue was up 8.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Activity

In other news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,717,841.12. The trade was a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 37,500 shares of company stock valued at $2,508,350 in the last ninety days. Insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on EW. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Morgan Stanley restated an “equal weight” rating and issued a $70.00 price target on shares of Edwards Lifesciences in a research note on Friday, October 11th. Daiwa America cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Citigroup boosted their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Finally, Piper Sandler reduced their price objective on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Sixteen investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Hold” and a consensus target price of $79.40.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.